エンスプリング新薬の考察と市場予測（2032年）

当レポートでは、主要7市場（米国・ドイツ・フランス・イタリア・スペイン・英国・日本）における全身型重症筋無力症（gMG）向けエンスプリングについて調査分析し、作用機序、用法と用量、研究開発活動についての考察、市場予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 全身性重症筋無力症におけるエンスプリングの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 治験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期の新しい治療法）

第5章 エンスプリングの市場の評価

• 全身型重症筋無力症におけるエンスプリングの市場の見通し
• 主要7市場の分析
  • 主要7市場の全身型重症筋無力症向けエンスプリングの市場規模
• 市場の分析：国別
  • 米国の全身型重症筋無力症向けエンスプリングの市場規模
  • ドイツの全身型重症筋無力症向けエンスプリングの市場規模
  • 英国の全身型重症筋無力症向けエンスプリングの市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: ENSPRYNG, Clinical Trial Description, 2023
• Table 2: ENSPRYNG, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: ENSPRYNG Market Size in the 7MM, in USD million (2019-2032)
• Table 6: ENSPRYNG Market Size in the US, in USD million (2019-2032)
• Table 7: ENSPRYNG Market Size in Germany, in USD million (2019-2032)
• Table 8: ENSPRYNG Market Size in France, in USD million (2019-2032)
• Table 9: ENSPRYNG Market Size in Italy, in USD million (2019-2032)
• Table 10: ENSPRYNG Market Size in Spain, in USD million (2019-2032)
• Table 11: ENSPRYNG Market Size in the UK, in USD million (2019-2032)
• Table 12: ENSPRYNG Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: ENSPRYNG Market Size in the 7MM, USD million (2019-2032)
• Figure 2: ENSPRYNG Market Size in the United States, USD million (2019-2032)
• Figure 3: ENSPRYNG Market Size in Germany, USD million (2019-2032)
• Figure 4: ENSPRYNG Market Size in France, USD million (2019-2032)
• Figure 5: ENSPRYNG Market Size in Italy, USD million (2019-2032)
• Figure 6: ENSPRYNG Market Size in Spain, USD million (2019-2032)
• Figure 7: ENSPRYNG Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: ENSPRYNG Market Size in Japan, USD million (2019-2032)

"ENSPRYNG Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about ENSPRYNG for Generalized Myasthenia Gravis (gMG) in the seven major markets. A detailed picture of the ENSPRYNG for generalized myasthenia gravis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ENSPRYNG for generalized myasthenia gravis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ENSPRYNG market forecast analysis for generalized myasthenia gravis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in generalized myasthenia gravis.

Drug Summary:

ENSPRYNG (satralizumab) is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor; gMG, a neuromuscular junction disorder, is caused by pathogenic autoantibodies. IL-6 plays important roles in T helper 17 (Th17), T follicular helper (Tfh), B-cell activation, and antibody production. Research shows that serum IL-6 levels were significantly increased and correlated with MG activity, which indicated the involvement of IL-6 in the pathogenesis of gMG through Th17, Tfh, and/or B-cells. Satralizumab is a selective IL-6R inhibitor and is administered subcutaneously.

ENSPRYNG was designed by Chugai Pharmaceutical, a subsidiary of Roche, using novel antibody recycling technology, which allows for a longer duration of antibody circulation and maximum inhibition of IL-6 signaling, while minimizing safety risks in a chronic disease setting. It is currently being studied in Phase III clinical trial as a monotherapy for the treatment of gMG in children and adults (patients aged 12 years or older).

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the ENSPRYNG description, mechanism of action, dosage and administration, research and development activities in generalized myasthenia gravis.
• Elaborated details on ENSPRYNG regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ENSPRYNG research and development activities in generalized myasthenia gravis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ENSPRYNG.
• The report contains forecasted sales of for generalized myasthenia gravis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for generalized myasthenia gravis.
• The report also features the SWOT analysis with analyst views for ENSPRYNG in generalized myasthenia gravis.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ENSPRYNG Analytical Perspective by DelveInsight

In-depth ENSPRYNG Market Assessment

This report provides a detailed market assessment of ENSPRYNG for generalized myasthenia gravis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

ENSPRYNG Clinical Assessment

The report provides the clinical trials information of ENSPRYNG for generalized myasthenia gravis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for generalized myasthenia gravis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ENSPRYNG dominance.
• Other emerging products for generalized myasthenia gravis are expected to give tough market competition to ENSPRYNG and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ENSPRYNG in generalized myasthenia gravis.
• Our in-depth analysis of the forecasted sales data of ENSPRYNG from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ENSPRYNG in generalized myasthenia gravis.

Key Questions

• What is the product type, route of administration and mechanism of action of ENSPRYNG?
• What is the clinical trial status of the study related to ENSPRYNG in generalized myasthenia gravis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ENSPRYNG development?
• What are the key designations that have been granted to ENSPRYNG for generalized myasthenia gravis?
• What is the forecasted market scenario of ENSPRYNG for generalized myasthenia gravis?
• What are the forecasted sales of ENSPRYNG in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to ENSPRYNG for generalized myasthenia gravis?
• Which are the late-stage emerging therapies under development for the treatment of generalized myasthenia gravis?

Table of Contents

1. Report Introduction

2. ENSPRYNG Overview in Generalized Myasthenia Gravis

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. ENSPRYNG Market Assessment

• 5.1. Market Outlook of ENSPRYNG in Generalized Myasthenia Gravis
• 5.2. 7MM Analysis
  • 5.2.1. Market size of ENSPRYNG in the 7MM for generalized myasthenia gravis
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market size of ENSPRYNG in the United States for generalized myasthenia gravis
  • 5.3.2. Market size of ENSPRYNG in Germany for generalized myasthenia gravis
  • 5.3.3. Market size of ENSPRYNG in France for generalized myasthenia gravis
  • 5.3.4. Market size of ENSPRYNG in Italy for generalized myasthenia gravis
  • 5.3.5. Market size of ENSPRYNG in Spain for generalized myasthenia gravis
  • 5.3.6. Market size of ENSPRYNG in the United Kingdom for generalized myasthenia gravis
  • 5.3.7. Market size of ENSPRYNG in Japan for generalized myasthenia gravis

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options